Pricing, Distribution, and Reimbursement
APONVIE is Priced to Support Broad Access, With Convenient Packaging and Distribution
340B: ≥23.1% discount
Vial contains single 32-mg dose. Packaged in cartons of 10 vials.
- Discounts available under contracts with leading GPOs
- 340B, sub-WAC, and FSS pricing available
- Distribution through authorized wholesalers and specialty distributors; prime vendor discounts apply
Note: Pricing as of March 3, 2023. 340B prices update quarterly. Confirm current pricing with your Heron representative.
WAC: wholesale acquisition cost.
GPO: group purchasing organization.
FSS: Federal Supply Schedule.
APONVIE Is Separately Reimbursed by Medicare in HOPDs and ASCsa
Effective April 1, 2023,
use C9145 when
billing for APONVIE
During 3-year pass-through statusa:
ASP + 6% in
HOPDs and ASCsb
APONVIE is the only product in its class separately reimbursed by Medicare in HOPDs and ASCsa
Generic PONV medications like oral aprepitant and other drugs without pass-through status are packaged across all settings of care.c
- Some commercial payers reimburse separately for APONVIE as a percentage of billed charges. However, most package APONVIE across all sites of care. Contact payers to verify coverage.
- Commercial payers have been notified of commercial availability and the product-specific code
Download the APONVIE Reimbursement Guide for more details.
aCoverage under 3-year transitional pass-through status effective April 1, 2023.
bAPONVIE will be reimbursed at WAC + 3% until ASP is established.
cReimbursement comparisons do not imply safety or efficacy.
HOPD: hospital outpatient department.
ASC: ambulatory surgical center.
ASP: average sales price.
WAC: wholesale acquisition cost.
Ordering and Pricing Information
Distribution Reference Guide
Heron Connect Website
[+] Expand[-] Collapse
Important Safety Information
APONVIE is contraindicated in patients with a history of hypersensitivity to aprepitant or any component of the product, and in patients taking pimozide. Increased pimozide levels may cause serious or life-threatening reactions, such as QT prolongation.
Warnings and Precautions
Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, during or soon after administration of aprepitant have occurred. Symptoms including dyspnea, eye swelling, flushing, pruritus, and wheezing have been reported. Monitor patients during and after administration. If hypersensitivity reactions occur, administer appropriate medical therapy. Do not administer APONVIE in patients who experienced these symptoms with previous use of aprepitant.
Clinically Significant CYP3A4 Drug Interactions: Aprepitant is a substrate, weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4. Use of pimozide, a CYP3A4 substrate, with APONVIE is contraindicated. Use of APONVIE with strong CYP3A4 inhibitors (eg, ketoconazole) may increase plasma concentrations of aprepitant and result in an increased risk of adverse reactions related to APONVIE. Use of APONVIE with strong CYP3A4 inducers (eg, rifampin) may result in a reduction in aprepitant plasma concentrations and decreased efficacy of APONVIE.
Decrease in INR with Concomitant Warfarin: Use of aprepitant with warfarin, a CYP2C9 substrate, may result in a clinically significant decrease in the International Normalized Ratio (INR) of prothrombin time. Monitor the INR in patients on chronic warfarin therapy in the 2-week period particularly at 7 to
Risk of Reduced Efficacy of Hormonal Contraceptives: The efficacy of hormonal contraceptives may be reduced for
Use in Specific Populations
Avoid use of APONVIE in pregnant women as alcohol is an inactive ingredient in APONVIE. There is no safe level of alcohol exposure in pregnancy.
Most common adverse reactions (incidence ≥3%) for APONVIE are constipation, fatigue, and headache and for oral aprepitant are constipation and hypotension.
Report side effects to Heron at
APONVIE is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.
Limitations of Use: APONVIE has not been studied for treatment of established nausea and vomiting.
Please see full Prescribing Information.
Connect with Heron
How could you incorporate APONVIE as the foundation of your institution's PONV management strategy? Connect with us to find out.
Fields marked with an asterisk (*) are required.
To report an adverse event or product complaint:
For general information:
Investors and Media:
For all other inquiries, please visit the Heron Therapeutics corporate website.
Go to Heron Website